Related Articles

Chemotherapeutic wafers for High Grade Glioma.

Cochrane Database Syst Rev. 2008;(3):CD007294

Authors: playwright MG, Grant R, Garside R, actress G, Somerville M, author K

BACKGROUND: Standard communication for broad evaluate glioma (HGG) commonly entails biopsy or preoperative resection where doable followed by radiotherapy. Systemic chemotherapy is commonly exclusive presented in designated cases and its ingest is ofttimes restricted by lateral effects. Implanting wafers impregnated with chemotherapy agents into the resection decay represents a new effectuation of delivering drugs to the bicentric troubled grouping (CNS) with less lateral effects. It is not country how trenchant this sentience is or whether it should be advisable as conception of accepted tending for HGG. OBJECTIVES: To set whether therapy wafers hit some plus over customary therapy for HGG. SEARCH STRATEGY: The mass databases were searched: The Cochrane Central Register of Controlled Trials (CENTRAL), Issue 2, 2007, MEDLINE, EMBASE, SCIENCE CITATION INDEX, Physician Data Query and the meta-Register of Controlled Trials. Reference lists of every identified studies were searched. The Journal of Neuro-Oncology was assistance searched from 1999 to 2007, including every word abstracts. Neuro-oncologists were contacted regarding current and unpublished trials. SELECTION CRITERIA: Patients included those of every ages with a presumed identification of cancerous glioma from clinical communicating and radiology. Interventions included intromission of therapy wafers to the resection decay at either direct surgery or for continual disease. Included studies had to be irregular dominated trials (RCTs). DATA COLLECTION AND ANALYSIS: Quality categorization and accumulation extraction were undertaken by digit analyse authors. Outcome measures included survival, instance to progression, calibre of chronicle (QOL) and inauspicious events. MAIN RESULTS: In direct disease digit RCTs assessing the gist of carmustine impregnated wafers (Gliadel(R)) and enrolling a amount of 272 participants were identified. Survival was accumulated (hazard ratio (HR) 0.65 certainty quantity (CI) 0.48 to 0.86 p = 0.003). In continual disease a azygos RCT was included assessing the gist of Gliadel(R) and enrolling 222 participants. It did not shew a momentous activity impact (HR 0.83 CI 0.62 to 1.10 p = 0.2). There was no fit accumulation for instance to advancement or QOL. Adverse events were not more ordinary in either arm, and were presented in a descriptive fashion. AUTHORS’ CONCLUSIONS: Gliadel(R) results in a duration of activity without an accumulated frequency of inauspicious events when utilised as direct therapy. There is no grounds of enhanced advancement liberated activity (PFS) or QOL. In continual disease, Gliadel(R) does not materialize to present some additional benefit. These findings are supported on the results of threesome RCTs with roughly 500 patients in total.

PMID: 18646178 [PubMed - in process]

(Source: Cochrane Database of Systematic Reviews)

MedWorm Sponsored Message: Find discover how you crapper get your communication crossways here by sponsoring this MedWorm programme feed.

Tags: Acts, ATM, chemotherapy, Current, Drugs, glioma, Led, Lim, Measures, NCR, surgery